OIG Urges Pay Change For DME Infusion Drugs To Curb Medicare Overpayments
This article was originally published in The Pink Sheet Daily
Executive Summary
Although CMS previously said it would include drugs infused with durable medical equipment in Medicare’s competitive bidding process for DME, it has not. So the Office of Inspector General is continuing to pressure the agency to make payment changes, citing overpayments of $251 million over six quarters in its latest report.